Search

everythinglearnresearchcommunity

for

Search:↓

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

The user is applying 0.4 mg of finasteride and 4 mg of minoxidil daily through a topical solution. This corresponds to a specific dosage analysis for hair loss treatment.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation discusses dosing for 1000mg Pumpkin Seed Oil tablets and compares its DHT-lowering effects to finasteride. The user considers splitting the tablets to achieve a 500mg dose.

The conversation discusses whether using pyrilutamide would interfere with minoxidil's ability to regrow hair, considering pyrilutamide is seen as a maintenance drug that stops shedding, while minoxidil promotes hair growth but causes initial shedding.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The user saw some improvement with topical minoxidil over 6-7 months and recently switched to oral minoxidil and finasteride, experiencing mild side effects from finasteride. They are concerned about losing gains from topical minoxidil and are seeking advice on whether to continue with the new regimen.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Oral minoxidil is generally more effective than topical minoxidil, despite higher side effect risks. Topical minoxidil can achieve higher bloodstream levels in some individuals, but effectiveness depends on conversion and scalp response.

Dutasteride doses matter for hair loss treatment and are more effective than finasteride. RU58841 is suggested for better gains, but side effect profiles should be considered.

Minoxidil may age skin by slowing collagen synthesis, but using collagen peptides and a basic skincare routine might counteract this. Foam minoxidil could reduce systemic absorption and avoid alcohol-related side effects.

A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

The user completed their first month using oral finasteride and topical minoxidil without issues but is concerned about a 2-3 day gap in their finasteride supply affecting progress. They are also seeking advice on obtaining a multi-month supply.

The post and conversation discuss different methods of applying hair loss treatments directly to the scalp. The original poster suggests using a 1ml TB Syringe & Ophthalmic Cannula for precise application, while others share their own methods, including sprays, droppers, and simple syringes.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

A user shared progress pictures and discussed their hair loss treatment, including using Hims spray with finasteride, oral finasteride, castor oil, and derma rolling. They reduced their Hims spray dose to every other day to minimize finasteride absorption into the bloodstream.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.

The user is seeking advice on effectively applying a liposomal solution of Minoxidil and Finasteride for hair loss, specifically targeting the roots without wasting the product. They find it challenging to use only 1 ml to cover thinning areas on the front and crown.

Long-term finasteride users report that the drug may lose effectiveness over time, with some considering switching to dutasteride or adding minoxidil to their regimen. Many users suggest hair transplants or adjusting treatments to manage hair loss progression.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

RU58841 and tretinoin are discussed for better absorption in hair loss treatment. The effectiveness of tretinoin with minoxidil is debated.